Form 4: Director Martha Shadan Receives Dividend Equivalent Rights
Statement of Changes in Beneficial Ownership
Director Martha Shadan of LeMaitre Vascular, Inc. reported the acquisition of dividend equivalent rights related to existing equity awards.
Summary
- Director Martha Shadan acquired a total of 4.0705 dividend equivalent rights on June 4, 2026.
- These rights accrued on previously granted restricted stock units and performance share units.
- Each dividend equivalent right represents the economic equivalent of one share of LeMaitre Vascular common stock.
- The acquisition of these rights is a standard administrative process following dividend declarations on underlying equity awards.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director equity holdings.
Positives
- Reflects ongoing alignment of director interests with shareholders through equity-based compensation.
- Demonstrates the company's commitment to dividend payments to equity holders.
Negatives
- None identified; this is a routine administrative filing.
Risks
- None identified; this filing relates to the accrual of dividend rights on existing holdings.
Future Outlook
No forward-looking guidance provided in this filing.
Industry Context
StockSavvy.ai notes that the accrual of dividend equivalent rights is a standard practice for directors holding equity-based compensation in medical device companies like LeMaitre Vascular, ensuring that directors are not economically disadvantaged by dividend distributions.
Comparison to Industry Standards
- The reporting of dividend equivalent rights is consistent with standard corporate governance practices for U.S. publicly traded companies.
- The structure of the equity awards aligns with typical compensation packages for board members in the healthcare sector.
Stakeholder Impact
- Minimal impact on shareholders as this represents the standard accrual of existing equity-based compensation.
Next Steps
- Vesting of the underlying restricted stock units and performance share units according to their respective grant schedules.
Key Dates
| Date | Description |
|---|---|
| 2023-12-08 | Grant date of initial restricted stock unit and performance share unit awards. |
| 2024-12-06 | Grant date of subsequent restricted stock unit and performance share unit awards. |
| 2025-12-10 | Grant date of additional restricted stock unit awards. |
| 2026-06-04 | Transaction date for the accrual of dividend equivalent rights. |
| 2026-06-05 | Filing date of the Form 4. |
Keywords
LeMaitre Vascular, LMAT, Form 4, Insider Trading, Dividend Equivalent Rights, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.